Vertex Pharmaceuticals Incorporated announced that Suketu Upadhyay elected to its board of directors as an independent director. Upadhyay is a global business executive with more than 20 years of experience in the pharmaceutical and medical technology sectors, serving in financial and strategy roles covering multiple areas of the life sciences sector. He is currently the Executive Vice President and Chief Financial Officer of Zimmer Biomet, a position he has held since July 2019.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
403.7 USD | +0.72% | +1.95% | -1.51% |
12:26pm | Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $497 From $515 | MT |
Apr. 23 | Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.11% | 22.2B | |
-16.53% | 21.23B | |
-10.28% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B | |
-24.93% | 8.22B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director